Not finding it? Sign in to also search OpenAlex live.
-
EOMES and IL-10 regulate anti-tumor activity of PD-1 + CD4 + T-cells in B-cell Non-Hodgkin lymphoma2020 bioRxiv (Cold Spring Harbor Laboratory) preprint Immunology and Microbiology T-cell and B-cell Immunology Open access
Philipp M. Roessner, Laura Llaó Cid, Ekaterina Lupar, Tobias Roider, Marie Bordas, Christoph Schifflers, +10 more
4citations -
Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment2023 Nature Communications article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 2 patents
Markus Haake, Beatrice Haack, Tina Schäfer, Patrick N. Harter, Greta Mattavelli, Patrick Eiring, +47 more
108citations -
PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer2020 Critical Reviews in Oncology/Hematology article Medicine Endometrial and Cervical Cancer Treatments Open access cited by 1 patent
Cathalijne Post, Anneke M. Westermann, Tjalling Bosse, Carien L. Creutzberg, Judith R. Kroep
61citations -
Immunophenotyping of T cells Combined with Vβ antibodies identifies long lasting CMV related T cell Expansions with a consistent TIGIT and PD-1 phenotype2024 bioRxiv (Cold Spring Harbor Laboratory) preprint Immunology and Microbiology T-cell and B-cell Immunology
Monique M. van Ostaijen-ten Dam, Marco W. Schilham, Arjan C. Lankester, Janine E. Melsen
0citations -
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
Georgina Venetia Long, Nitya Nair, Daniel Marbach, Richard A. Scolyer, Sabine Wilson, Denise Cotting, +19 more
23citations -
PD-1 Overexpression in Sézary Syndrome Is Epigenetically Regulated2023 Journal of Investigative Dermatology article Medicine Cutaneous lymphoproliferative disorders research Open access
Safa Najidh, Willem H. Zoutman, Anne M.R. Schrader, Rein Willemze, Cornelis P. Tensen, Maarten H. Vermeer
1citations -
PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice2024 Journal of Clinical Investigation article Medicine Cancer Immunotherapy and Biomarkers Open access
Elselien Frijlink, Douwe M. T. Bosma, Julia Busselaar, Thomas Battaglia, Mo D. Staal, Inge Verbrugge, +1 more
36citations -
1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01
Mariana Brandão, J.T.J.N. Hiltermann, Els Wauters, Benjamin J. Solomon, Eduardo Castañón Álvarez, Enriqueta Felip, +12 more
12citations -
Decidual NK cells, extravillous trophoblast and their PD-1/PD-L1 interaction: New insights into recurrent pregnancy loss and placenta accreta spectrum disorders2026 Immunology Letters article Immunology and Microbiology Reproductive System and Pregnancy Open access
Anna Moscheik, Denise H. J. Habets, Irmgard Classen-Linke, Ulrike von Rango, C. Severens‐Rijvers
1citations -
Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial
Evalyn E.A.P. Mulder, Karlijn de Joode, Saskia Litière, Albert J. ten Tije, Karijn P.M. Suijkerbuijk, M. J. Boers‐Sonderen, +16 more
50citations -
PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients2026 Frontiers in Immunology article Immunology and Microbiology Immunotherapy and Immune Responses Open access
Séverine Planel, Guillaume Vayssière, Gianni Maggipinto, Estelle Leplus, Karine Laulagnier, Françoise Myster, +21 more
0citations -
Abstract 1182: PDC*lung01: An innovative therapeutic cancer vaccine induces specific immune responses in combination with anti- PD-1 treatment in patients with non-small cell lung cancer2024 Cancer Research conference-abstract Immunology and Microbiology Immunotherapy and Immune Responses
Joël Plumas, Anne Sibille, Ingel Demedts, Elvire Pons Tostivint, Charlotte Van de Kerkhove, Sofie Derijcke, +16 more
0citations -
Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis2023 Cancers article Biochemistry, Genetics and Molecular Biology Melanoma and MAPK Pathways Open access
Melissa Melanie de Meza, Willeke A.M. Blokx, Johannes J. Bonenkamp, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, +14 more
16citations -
Combination immunotherapy with synthetic long peptides and chemotherapy or PD-1 blocker for cancers caused by human papilloma virus type 162023 Seminars in Immunopathology article Immunology and Microbiology Immunotherapy and Immune Responses
Cornelis J.M. Melief, Esmé T.I. van der Gracht, Anna‐Sophia Wiekmeijer
6citations -
AI-detected tumor-infiltrating lymphocytes and response to PD-1 based treatment in advanced melanoma.2025 Journal of Clinical Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
Mark Schuiveling, Isabella A.J. van Duin, Laurens S. ter Maat, Janneke C. van der Weerd, Franchette W.P.J. van den Berkmortel, Femke H. Burgers, +14 more
1citations